There is a statistic buried in the endocrinology literature that does not get nearly enough attention in the spaces where men actually talk about their health. It appeared in a 2008 analysis of the European Male Aging Study (EMAS), a large multicenter cohort study of men in eight European countries. It went roughly like this:
Obese men have an 8.7-fold increased risk of secondary hypogonadism compared to men of normal weight.
Not 8.7%. Not “meaningfully higher.” Eight point seven times the risk.
If a drug doubled your risk of something, you’d read about it. An 8.7-fold increase in the risk of clinically meaningful testosterone deficiency, attributable to obesity — not genetics, not testicular disease, not pituitary pathology, but carrying excess body fat — ought to be a major public health conversation. Instead, it mostly sits in the methods sections of papers that most people will never read.
This series is about that conversation.
The EMAS and Where That Number Comes From
The European Male Aging Study enrolled 3,369 men aged 40 to 79 across eight European cities, making it one of the largest and most rigorous prospective studies of male aging and hormone levels ever conducted. The cohort was a community sample — not men seeking treatment, not men already diagnosed — which means the findings reflect what is actually happening in the general population.
The 2008 analysis specifically examined the relationship between body weight and secondary hypogonadism. The researchers defined secondary hypogonadism as total testosterone below 10.5 nmol/L (approximately 302 ng/dL) combined with normal or low levels of luteinizing hormone (LH) — indicating that the problem was in the control axis (hypothalamus and pituitary) rather than in the testes themselves.
The finding was stark: compared to men with normal BMI, obese men (BMI ≥ 30) had an 8.7-fold increased relative risk of meeting criteria for secondary hypogonadism. Overweight men (BMI 25–30) had a 3.3-fold increased risk.
Both total testosterone and free testosterone were substantially lower in obese men: total testosterone was 5.9 nmol/L lower in obese men compared to lean men, and free testosterone was 54 pmol/L lower.
Primary vs. Secondary: Why the Distinction Matters
It is worth pausing on the classification system here, because the type of hypogonadism tells you where in the hormonal control chain things went wrong — and that shapes both the clinical picture and the treatment approach.
Primary hypogonadism is a problem in the testes themselves. The testes cannot produce adequate testosterone due to genetic conditions (like Klinefelter syndrome, where men have XXY chromosomes), physical damage (trauma, surgery, infection), radiation, or other direct testicular insults. In primary hypogonadism, the brain is trying to stimulate testosterone production — it sends the signal (LH is elevated) — but the testes can’t respond.
Secondary hypogonadism (also called central or functional hypogonadism) is a problem upstream. The hypothalamus and pituitary are not sending adequate stimulatory signals, or the signals are being suppressed. LH is low or inappropriately normal given the low testosterone. The testes, in principle, are capable of producing testosterone — they’re just not being adequately driven to do so.
Obesity-associated hypogonadism is predominantly secondary (functional). The testes haven’t failed. The control system has been suppressed. This is an important distinction because it means the condition is, at least in principle, reversible — with adequate weight loss, in many men, the hypothalamic-pituitary-testicular (HPT) axis can reactivate and testosterone can recover.
The operative phrase is “with adequate weight loss.” We will return to what “adequate” means. It is not a small number.
Why Obesity Specifically?
Among the many health conditions that affect testosterone levels — sleep apnea, type 2 diabetes, opioid use, glucocorticoid use, pituitary tumors, to name some common ones — obesity occupies a distinctive position as the most powerful single predictor of low testosterone in community-dwelling men.
A longitudinal analysis from the EMAS showed that in the Massachusetts Male Aging Study (MMAS), moving from a non-obese to an obese state resulted in a decline in testosterone comparable to aging approximately 10 years. Not 10% of a decade. Ten years of typical age-related testosterone decline, accomplished by accumulating excess body fat.
Multiple cross-sectional studies across different ethnicities and geographies have shown the same negative linear correlation: the higher the BMI, the lower the testosterone. This relationship persists after adjusting for age, comorbidities, and smoking status. A cross-sectional study of 1,849 community-dwelling American men found that 40% of obese men had low testosterone levels. In men with BMI above 35–40 kg/m², more than 50% have both total and free testosterone levels reduced compared to lean controls.
This is not a niche problem. In the United States as of 2023, more than one in three adults in many states meets criteria for obesity. The prevalence of functional hypogonadism attributable to obesity, extrapolated across the population, represents an enormous and largely underrecognized burden of hormonal dysfunction.
The Concept of Functional Hypogonadism
The terminology in this area is still evolving. “Functional hypogonadism” or “functional hypogonadotropic hypogonadism” refers specifically to the reversible suppression of the HPT axis by factors like obesity, illness, or medications — as distinct from “organic hypogonadism” which involves structural damage to the testes, hypothalamus, or pituitary.
This distinction has regulatory implications (the FDA, as discussed in Series 5, technically limits testosterone approvals to organic hypogonadism) and it has clinical implications. A man with functional hypogonadism from obesity who loses 15% of his body weight may see meaningful testosterone recovery without ever requiring exogenous therapy. A man with Klinefelter syndrome will not — his primary hypogonadism reflects chromosomal biology that weight loss cannot reverse.
But for the large number of men whose testosterone deficiency is driven primarily by excess adipose tissue — the 8.7-fold risk population — the biology is more modifiable than most people realize. The question is mechanism: exactly how does being overweight suppress testosterone production at the level of the HPT axis?
That answer involves adipose tissue, an enzyme called aromatase, and a conversion process that turns testosterone into estrogen at a rate that scales with how much fat you’re carrying.
Next up: Post 2 — “The Fat Cell Problem: How Your Adipose Tissue Is Moonlighting as an Estrogen Factory, and What That Does to Your Testosterone.”
